Total medical devices industry deals for Q1 2019 worth $11.78bn were announced globally, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked a decrease of 11.2% over the previous quarter and a drop of 10.6% when compared with the last four-quarter average of $13.18bn.
In terms of number of deals, the sector saw a rise of 3.1% over the last four-quarter average with 337 deals against the average of 327 deals.
In value terms, North America led the activity with deals worth $10.24bn.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataMedical devices industry deals in Q1 2019: Top deals
The top five medical devices deals accounted for 72.3% of the overall value during Q1 2019.
The combined value of the top five medical devices deals stood at $8.51bn, against the overall value of $11.78bn recorded for the quarter. The top announced medical devices deal tracked by GlobalData in Q1 2019 was Johnson & Johnson’s $5.75bn acquisition of Auris Health.
In second place was the $1.14bn asset transaction with Thermo Fisher Scientific by PHC and in third place was Ontario Teachers’ Pension Plan and Silver Lake Partners’ $1bn private equity deal with Verily Life Sciences.
The $339.05m private equity deal with Dutch Ophthalmic Research Center International by Eurazeo and Alcon Laboratories’ acquisition of PowerVision for $285m held fourth and fifth positions, respectively.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.
